You are here

FDA Accepts Application for Afatinib (Gilotrif) for Treatment of Advanced Lung Cancer

Pivotal trial shows delayed disease progression versus erlotinib

The FDA has accepted a filing application for afatinib (Gilotrif, Boehringer Ingelheim) for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. Afatinib has also been granted an “orphan drug” designation by the FDA –– a status given to a product intended for the treatment of a rare disease or condition.

The submission was based on data from the phase III LUX-Lung 8 trial, which compared afatinib with erlotinib (Tarceva, Genentech/Astellas Oncology) in patients with advanced SCC of the lung progressing after treatment with first-line platinum-based chemotherapy. Data from this study showed that treatment with afatinib resulted in superior progression-free survival (the trial’s primary endpoint), reducing the risk of cancer progression by 19%, and superior overall survival (the key secondary endpoint), reducing the risk of death by 19%, compared with erlotinib in this patient population.

A higher incidence of severe diarrhea and stomatitis was observed with afatinib compared with erlotinib (grade-3 diarrhea: 10% vs. 2%, respectively; grade-3 stomatitis: 4% vs. 0%), whereas a higher incidence of severe rash/acne was reported with erlotinib compared with afatinib (grade-3 rash/acne: 10% vs. 6%).

Non–small-cell lung cancer (NSCLC) is the most common form of lung cancer, comprising over 85% of lung cancer cases. SCC develops in the cells lining the airways and represents approximately 30% of NSCLC cases. SCC of the lung is associated with a poor prognosis and limited survival. The median overall survival after a diagnosis of advanced SCC is approximately 1 year.

Afatinib, an oral, once-daily epidermal growth factor receptor (EGFR)-directed therapy, is currently approved in more than 60 countries for the first-line treatment of specific types of EGFR mutation-positive NSCLC. In the U.S., afatinib is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.

Source: Boehringer Ingelheim; August 25, 2015.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress